A2B Adenosine Receptor as a novel target in cancer immunotherapy: Validation and optimization of new ligands
Por favor, use este identificador para citas ou ligazóns a este ítem:
http://hdl.handle.net/10347/31288
Ficheiros no ítem
Metadatos do ítem
Título: | A2B Adenosine Receptor as a novel target in cancer immunotherapy: Validation and optimization of new ligands |
Autor/a: | Prieto Díaz, Rubén |
Dirección/Titoría: | Sotelo Pérez, Eddy |
Centro/Departamento: | Universidade de Santiago de Compostela. Escola de Doutoramento Internacional (EDIUS) Universidade de Santiago de Compostela. Programa de Doutoramento en Investigación e Desenvolvemento de Medicamentos |
Palabras chave: | adenosine | A2BAR | immunotherapy | |
Data: | 2023 |
Resumo: | This doctoral thesis focuses on the study of purinergic signaling in cancer, specifically targeting adenosine receptors. The main objective is the development of potent and selective nonxanthine- based antagonists for adenosine A2B receptors, with potential applications in cancer-targeted therapies. Molecular design strategies, synthesis, biological evaluation, structureactivity relationships, enantiospecific recognition and molecular modeling are explored. To the end, a rational method for dual A2A/A2B antagonists were obtained. The optimization and preclinical validation of new ligands for cancer (immuno)therapy are investigated, revealing promising data in terms of pharmacokinetics and pharmacodynamics. |
Data de Embargo: | 2024-10-06 |
URI: | http://hdl.handle.net/10347/31288 |
Dereitos: | Attribution-NonCommercial-NoDerivatives 4.0 Internacional |
Coleccións
-
- Área de Ciencias da Saúde [1262]
O ítem ten asociados os seguintes ficheiros de licenza: